Home > Insider Trading > Filing (0001104659-16-131410)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1556263	Syros Pharmaceuticals Inc.	SYRS	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1425738	Redmile Group, Llc	One Letterman Drive, Building D, Suite D3-300 San Francisco CA 94129		No	No	Yes	No
1650527	Jeremy Green	One Letterman Drive, Building D, Suite D3-300 San Francisco CA 94129		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-07-06	84,760	$0.00	84,760	No	4	C	Direct
Common Stock	Acquisiton	2016-07-06	47,486	$0.00	47,486	No	4	C	Direct
Common Stock	Acquisiton	2016-07-06	262,069	$0.00	262,069	No	4	C	Direct
Common Stock	Acquisiton	2016-07-06	31,447	$0.00	31,447	No	4	C	Direct
Common Stock	Acquisiton	2016-07-06	40,420	$0.00	40,420	No	4	C	Direct
Common Stock	Acquisiton	2016-07-06	144,383	$12.50	191,869	No	4	P	Direct
Common Stock	Acquisiton	2016-07-06	104,670	$12.50	366,739	No	4	P	Direct
Common Stock	Acquisiton	2016-07-06	174,320	$12.50	205,767	No	4	P	Direct
Common Stock	Acquisiton	2016-07-06	9,373	$12.50	49,793	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	317,853	$0.00	84,760	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	178,074	$0.00	47,486	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	982,762	$0.00	262,069	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	117,931	$0.00	31,447	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	151,576	$0.00	40,420	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
These shares are owned directly by Redmile Biopharma Investments I, L.P.
These shares are owned directly by Redmile Capital Fund LP.
These shares are owned directly by Redmile Capital Offshore Fund II, Ltd.
These shares are owned directly by Redmile Capital Offshore Fund, Ltd.
These shares are owned directly by Redmile Special Opportunities Fund, Ltd.